El sistema híbrido avanzado Tandem Control-IQ mejora el control glucémico en menores de 18 años con diabetes tipo 1 y el descanso nocturno de los cuidadores

Cheema, 2018, Risk factors for microvascular complications of diabetes in a high-risk Middle East population, J Diabetes Res., 2018, 8964027, 10.1155/2018/8964027 Svensson, 2004, Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type1 diabetes: A population-based study in northern Sweden, Diabetes Care., 27, 955, 10.2337/diacare.27.4.955 Feldman, 2019, Diabetic neuropathy, Nat Rev Dis Primers., 5, 42, 10.1038/s41572-019-0092-1 Battelino, 2019, Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range, Diabetes Care., 42, 1593, 10.2337/dci19-0028 Kovatchev, 2017, Metrics for glycaemic control — from HbA1c to continuous glucose monitoring, Nat Rev Endocrinol., 13, 425, 10.1038/nrendo.2017.3 Choudhary, 2019, Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with type 1 diabetes: A real-world study in the UK, Diabet Med., 36, 1100, 10.1111/dme.14043 Pozzilli, 2016, Continuous subcutaneous insulin infusion in diabetes: Patient populations, safety, efficacy, and pharmacoeconomics, Diabetes Metab Res Rev., 32, 21, 10.1002/dmrr.2653 Musolino, 2019, Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes, Pediatr Diabetes., 20, 794 Foster, 2019, State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018, Diabetes Technol Ther., 21, 66, 10.1089/dia.2018.0384 Tauschmann, 2014, Insulin pump therapy in youth with type 1 diabetes: Toward closed-loop systems, Expert Opin Drug Deliv., 11, 943, 10.1517/17425247.2014.910192 Aleppo, 2018, Integrated insulin pump and continuous glucose monitoring technology in diabetes care today: A perspective of real-life experience with the Minimed™ 670G Hybrid Closed-Loop System, Endocr Pract., 24, 684, 10.4158/EP-2018-0097 Brown, 2018, First look at Control-IQ: A new-generation automated insulin delivery system, Diabetes Care., 41, 2634, 10.2337/dc18-1249 Forlenza, 2019, Successful at-home use of the Tandem Control-IQ artificial pancreas system in young children during a randomized controlled trial, Diabetes Technol Ther., 21, 159, 10.1089/dia.2019.0011 Ekhlaspour, 2021, Safety and performance of the Tandem t:slim X2 with Control-IQ automated insulin delivery system in toddlers and preschoolers, Diabetes Technol Ther., 23, 384, 10.1089/dia.2020.0507 Pinsker, 2020, Real-world improvements in hypoglycemia in an insulin-dependent cohort with diabetes mellitus pre/post Tandem Basal-Iq technology remote software update, Endocr Pract., 26, 714, 10.4158/EP-2019-0554 Forlenza, 2018, Predictive low-glucose suspend reduces hypoglycemia in adults adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial, Diabetes Care., 41, 2155, 10.2337/dc18-0771 O’Malley, 2021, Clinical management and pump parameter adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-month, multicenter, randomized clinical trial, Diabetes Technol Ther., 23, 245, 10.1089/dia.2020.0472 Manning, 2020, The development and psychometric validation of the diabetes impact and device satisfaction scale for individuals with type 1 diabetes, J Diabetes Sci Technol., 14, 309, 10.1177/1932296819897976 Pinsker, 2021, Real-world patient-reported outcomes and glycemic results with initiation of Control-IQ technology, Diabetes Technol Ther., 23, 120, 10.1089/dia.2020.0388 DiMeglio, 2018, ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes, Pediatr Diabetes., 19, 105, 10.1111/pedi.12737 Schoelwer, 2021, Predictors of time-in-range (70-180?mg/dL) achieved using a closed-loop control system, Diabetes Technol Ther., 23, 475, 10.1089/dia.2020.0646 Breton, 2020, A randomized trial of closed-loop control in children with type 1 diabetes, N Engl J Med., 383, 836, 10.1056/NEJMoa2004736 Forlenza, 2019, Safety evaluation of the MiniMed 670G System in children 7-13 years of age with type 1 diabetes, Diabetes Technol Ther., 21, 11, 10.1089/dia.2018.0264 Bassi, 2022, A comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes, Front Endocrinol (Lausanne)., 12, 802419, 10.3389/fendo.2021.802419 Carlson, 2020, 97-LB: Safety and glycemic outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) system in subjects with T1D, Diabetes., 69, 97, 10.2337/db20-97-LB Collyns, 2021, Improved glycemic outcomes with Medtronic MiniMed Advanced Hybrid Closed-Loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes, Diabetes Care., 44, 969, 10.2337/dc20-2250 Breton, 2021, One year real-world use of the Control-IQ advanced hybrid closed-loop technology, Diabetes Technol Ther., 23, 601, 10.1089/dia.2021.0097 Messer, 2020, Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months, Pediatr Diabetes., 21, 319, 10.1111/pedi.12971 Messer, 2021, Basal-IQ technology in the real world: Satisfaction and reduction of diabetes burden in individuals with type 1 diabetes, Diabet Med., 38, e14381, 10.1111/dme.14381 Wheeler, 2022, Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with type 1 diabetes in a randomized crossover trial, Acta Diabetol., 59, 31, 10.1007/s00592-021-01789-5